A Phase I/II, Open Label, Single Arm, Two Part Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti Tumor Activity of glofitamab in Combination with Chemoimmunotherapy in Pediatric and Young Adult Participants with Relapsed/Refractory Mature B-cell Non-Hodgkin Lymphoma

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT05533775

Study #:
CMH - CO43810

Start Date:
Sep 01, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05533775

View Complete Trial Details & Eligibility at ClinicalTrials.gov